Abstract:Osteoporosis, characterized by an imbalance in bone homeostasis, is a global health concern. Bone defects are difficult to heal in patients with osteoporosis. Classical drug treatments for osteoporotic bone defects have unsatisfactory efficacy owing to side effects and imprecise delivery problems. In this study, a magnetic aggregation‐induced bone‐targeting poly(lactic‐co‐glycolic acid, PLGA)‐based nanocarrier (ZOL‐PLGA@Yoda1/SPIO) is synthesized to realize dual‐targeted delivery and precise Piezo1‐activated therapy for osteoporotic bone defects. Piezo1 is an important mechanotransducer that plays a key role in regulating bone homeostasis. To achieve dual‐targeting properties, ZOL‐PLGA@Yoda1/SPIO is fabricated using zoledronate (ZOL)‐decorated PLGA, superparamagnetic iron oxide (SPIO), and Piezo1‐activated molecule Yoda1 via the emulsion solvent diffusion method. Bone‐targeting molecular mediation and magnetic aggregation‐induced properties can jointly and effectively achieve precise delivery to localized bone defects. Moreover, Yoda1 loading enables targeted and efficient mimicking of mechanical signals and activation of Piezo1. Experiments in vivo and in vitro demonstrate that ZOL‐PLGA@Yoda1/SPIO can activate Piezo1 in bone defect areas of osteoporotic mice, improve osteogenesis through YAP/β‐catenin signaling axis, promote a well‐coordinated osteogenesis–angiogenesis coupling, and significantly accelerate bone reconstruction within the defects without noticeable side effects. Overall, this novel dual‐targeting nanocarrier provides a potentially effective strategy for the clinical treatment of osteoporotic bone defects. This article is protected by copyright. All rights reserved

Structural Modification and Pharmacological Evaluation of (Thiadiazol-2-yl)pyrazines as Novel Piezo1 Agonists for the Intervention of Disuse Osteoporosis

A Novel Piezo1 Agonist Promoting Mesenchymal Stem Cell Proliferation and Osteogenesis to Attenuate Disuse Osteoporosis

Correction to "Structural Modification and Pharmacological Evaluation of (Thiadiazol-2-yl)pyrazines as Novel Piezo1 Agonists for the Intervention of Disuse Osteoporosis"

Synthesis, Crystal Structures, Fluorescence and Xanthine Oxidase Inhibitory Activity of Pyrazole-Based 1,3,4-Oxadiazole Derivatives

Improved PIEZO1 agonism through 4‐benzoic acid modification of Yoda1

Exploring the Structural Attributes of Yoda1 for the Development of New-Generation Piezo1 Agonist Yaddle1 as a Vaccine Adjuvant Targeting Optimal T Cell Activation

Novel Pyrazole Derivatives Effectively Inhibit Osteoclastogenesis, a Potential Target for Treating Osteoporosis

Levering Mechanically Activated Piezo Channels for Potential Pharmacological Intervention

Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors

Pharmacology of PIEZO1 channels

Levering Mechanically Activated Piezo Channels for Potential Pharmacological Intervention.

Structural Analysis of (S)-1-((1h-benzo[d][1,2,3]triazol-1-yl)oxy)-3-(4-(2-methoxyphenyl)piperazin-1-yl)propan-2-ol and Binding Mechanism with Α1a-Adrenoceptor: TDDFT Calculations, X-ray Crystallography and Molecular Docking

Design, Synthesis, and Structure–activity-Relationship of Tetrahydrothiazolopyridine Derivatives As Potent Smoothened Antagonists

Synthesis and Biological Evaluation of Novel Piperidine-3-Carboxamide Derivatives as Anti-Osteoporosis Agents Targeting Cathepsin K

Synthesis, Preliminary Pharmacological Evaluation and Receptor Docking Studies of 10-Amino-3-methoxy-6,8,12,12a-tetrahydro-5h-thiazolo[4',5':4,5]Pyrido[2,1-a]isoquinolin-2-ols As Novel Dopamine D1 Receptor Inhibitors

Magnetic Aggregation‐Induced Bone‐Targeting Nanocarrier with Effects of Piezo1 Activation and Osteogenic–Angiogenic Coupling for Osteoporotic Bone Repair

Optimization of 6-Heterocyclic-2-(1h-pyrazol-1-yl)-n-(pyridin-2-yl)pyrimidin-4-amine As Potent Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease.

Raloxifene-driven benzothiophene derivatives: Discovery, structural refinement, and biological evaluation as potent PPARγ modulators based on drug repurposing

Design, synthesis and evaluation of a pyrazolo[3,4-d]pyrimidine derivative as a novel and potent TGFβ1R1 inhibitor

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Synthesis, crystal structure, anti-bone cancer activity and molecular docking investigations of the heterocyclic compound 1-((2S,3S)-2-(benzyloxy)pentan-3-yl)-4-(4-(4-(4-hydroxyphenyl)piperazin-1-yl) phenyl)-1H-1,2,4-triazol-5(4H)-one